MyoKardia Announces Twelve Abstracts Accepted for Presentation During the 2018 American Heart Association Scientific Sessions
Presentations Include Data from Ongoing Clinical Trials and Preclinical Studies of Mavacamten and HCM Population Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
MyoKardia Management to Host a Conference Call on November 12 at 8:00 a.m. ET to Review Data
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced the presentation of twelve abstracts at the upcoming American Heart Association (AHA) Scientific Sessions 2018 taking place November 10-12, 2018 in Chicago. These abstracts include new data from ongoing clinical trials and preclinical studies of mavacamten, as well as new population insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).
Among the highlights of the data being presented are an analysis of mavacamten’s effect on left ventricular relaxation based on patient data from the Phase 2 PIONEER-HCM clinical trial, which will be presented on Saturday, November 10, and an oral presentation on Sunday, November 11 examining the in vivo effect of myosin inhibition in a proprietary large-animal model of non-obstructive hypertrophic cardiomyopathy (HCM).
A complete list of planned MyoKardia and SHaRe research presentations is detailed below:
Saturday, November 10
Session HCM
11:30 a.m. – 12:45 p.m. CT
POSTER: Peak Oxygen Consumption is an Independent Predictor of Survival and Outcomes in Obstructive and Non-Obstructive Hypertrophic Cardiomyopathy (HCM) Patients: Results from the International Sarcomeric Human Cardiomyopathies Registry (SHaRe)
Lead author: Sharlene M Day, M.D., University of Michigan Medical School, Ann Arbor, MI
11:30 a.m. – 12:45 p.m. CT
MODERATED POSTER: Reclassifying Hypertrophic Cardiomyopathy Variants of Unknown Significance Based on Structural Determinants Improves Risk Stratification
Lead author: Amanda C Garfinkel, Harvard Medical School, Boston, MA
Session Heart Failure Outcomes
2:15 p.m. – 3:30 p.m. CT
POSTER: EXPLORER-HCM: Phase 3 Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate Mavacamten (MYK-461) In Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Lead author: Iacopo Olivotto, Careggi Univ Hosp, Florence, Italy
2:15 p.m. – 3:30 p.m. CT
POSTER: MAVERICK-HCM: Phase 2 Randomized, Multi-Center, Double-Blind, Placebo-Controlled Concentration Guided Study to Evaluate Mavacamten (Myk-461) In Adults with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Lead author: Stephen Heitner, M.D., Oregon Health & Sciences University, Portland, OR
Session: Potpourri of HCM
3:30 p.m. – 3:35 p.m. CT
MODERATED POSTER: Mavacamten Improves Left Ventricular Relaxation and Compliance in oHCM Through Direct Myosin Modulation
Lead author: Stephen Heitner, M.D., Oregon Health & Sciences University, Portland, OR
3:50 p.m. - 3:55 p.m. CT
MODERATED POSTER: Women with Hypertrophic Cardiomyopathy: Obstructed and Underdiagnosed? Results from the International SHaRe Registry
Lead author: Carolyn Y Ho, MD, Brigham and Women's Hospital, Boston, MA
4:10 p.m. - 4:15 p.m. CT
MODERATED POSTER: Obesity is a Major Driver of Obstruction and HF in HCM: Results from the International SHaRe Registry
Lead author: Carlo Fumagalli, M.D., University of Florence, Florence, Italy
Sunday, November 11
Session: New Insights into Hypertrophic and Noncompaction Cardiomyopathy
10:25 a.m. - 10:30 a.m. CT
MODERATED POSTER: Precision Approach to Exercise Capacity and Outcome in HCM an International Multicenter Analysis
Lead author: Seung-Pyo Lee, MD, PhD, Seoul National University Hospital, Seoul, Korea
Session: Health disparities
10:30 a.m. - 11:45 a.m. CT
POSTER: Impact of Race on Disease Expression and Clinical Outcomes in HCM
Lead author: Lauren A Eberly, MD, Brigham and Women's Hospital, Boston, MA
10:35 a.m. - 10:40 a.m. CT
MODERATED POSTER: Functional Clustering of Non-Truncating Mutations in Myosin Binding Protein C that Cause Hypertrophic Cardiomyopathy
Lead author: Andrea D. Thompson, MD, University of Michigan Medical School, Ann Arbor, M;
Session: Women and Special Populations: Digital Moderated Session
12:35 p.m. - 12:40 p.m. CT
MODERATED POSTER:
Lead author: Neal K Lakdawala, MD, Brigham and Women's Hospital, Boston, MA;
Drug Discovery-Heart Failure Oral Abstracts Session I
4:30 p.m. - 4:45 p.m. CT
ORAL PRESENTATION: Acute Effects of a Small-Molecule Direct Myosin-Attenuator (MYK-581) in a Mini-Pig Genetic Model of Non-Obstructed Hypertrophic Cardiomyopathy: In Vivo Evidence for Contractile Regulation with Improved Compliance and Functional Reserve
Lead author: Carlos del Rio, PhD, MyoKardia, Inc.
Conference Call and Webcast
Myokardia management will host a conference call to discuss data being presented at the AHA Scientific Sessions on November 12, 2018 at 8:00 a.m. ET. Investors and analysts are invited to participate in the call by dialing (U.S.) or using the conference ID 8998385. The webcast may be accessed live on the Investor Relations section of the MyoKardia website at . A replay of the webcast will be available on MyoKardia’s website for 90 days following the call.
About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the development of small molecule therapeutics aimed at the cardiac muscle proteins that modulate cardiac muscle contraction and underlie diseases of systolic and diastolic dysfunction. Based on an in-depth understanding of disease biology, MyoKardia applies a precision medicine approach to develop its therapeutic candidates for patient populations with shared characteristics, such as causal genetic mutations or disease subtypes. MyoKardia’s most advanced product candidate is mavacamten (formerly MYK-461), a novel, oral, allosteric modulator of cardiac myosin intended to reduce hypercontractility. Mavacamten has advanced into a pivotal Phase 3 clinical trial, known as EXPLORER-HCM in patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM). MyoKardia is also developing mavacamten in a second indication, non-obstructive HCM, in the Phase 2 MAVERICK-HCM clinical trial. MYK-491, MyoKardia’s second product candidate, is designed to increase cardiac output among patients with systolic heart dysfunction by increasing the overall extent of the heart’s cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1b/2a study in stable heart failure patients. MyoKardia has formed a collaboration with Sanofi to support the commercialization of mavacamten outside the U.S. and for MYK-491’s worldwide late-stage development and commercialization. MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.
Contacts:
Michelle Corral
Senior Director, Corporate Communications and Investor Relations
MyoKardia, Inc.
650-351-4690
Hannah Deresiewicz (investors)
Stern Investor Relations, Inc.
212-362-1200
Steven Cooper (media)
Edelman
415-486-3264
